Ciclesonide
- Generic Name
- Ciclesonide
- Brand Names
- Alvesco, Omnaris, Zetonna
- Drug Type
- Small Molecule
- Chemical Formula
- C32H44O7
- CAS Number
- 126544-47-6
- Unique Ingredient Identifier
- S59502J185
- Background
Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
- Indication
For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
- Associated Conditions
- Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2005-12-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 450
- Registration Number
- NCT00270348
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00261287
- Locations
- 🇺🇸
Altana Pharma/Nycomed, San Antonio, Texas, United States
Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00163384
- Locations
- 🇰🇷
Altana Pharma/Nycomed, Seoul, Korea, Republic of
Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT00163488
- Locations
- 🇺🇸
Altana Pharma/Nycomed, Long Beach, California, United States
Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT00163371
- Locations
- 🇩🇰
Altana Pharma/Nycomed, Kolding, Denmark
Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00163397
- Locations
- 🇨🇳
Altana Pharma/Nycomed, Taipei, Taiwan
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00163462
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Wynberg, South Africa
Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT00163358
- Locations
- 🇪🇸
Altana Pharma/Nycomed, Valencia, Spain
Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 480
- Registration Number
- NCT00163423
- Locations
- 🇿🇦
Altana Pharma/Nycomed, Wynberg, South Africa
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00163345
- Locations
- 🇳🇱
Altana Pharma/Nycomed, RB Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath